

A phase II study of first-line afatinib for patients aged ≥ 75 years with *EGFR* mutation-positive advanced non-small cell lung cancer: North East Japan Study Group Trial NEJ027

Yuji Minegishi (✉ yminegis@nms.ac.jp)

Graduate School of Medicine, Nippon Medical School <https://orcid.org/0000-0001-5023-8058>

Ou Yamaguchi

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University

Shunichi Sugawara

Department of Pulmonary Medicine, Sendai Kousei Hospital

Shoichi Kuyama

National Hospital Organization Iwakuni Clinical Center

Satoshi Watanabe

Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences

Kazuhiro Usui

Division of Respiriology, NTT Medical Center

Masahide Mori

National Hospital Organization Osaka Toneyama Medical Center

Osamu Hataji

Respiratory Center, Matsusaka Municipal Hospital

Toshihiro Nukiwa

Tohoku University

Satoshi Morita

Department Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine

Kunihiko Kobayashi

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University

Akihiko Gemma

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School

Research article

Keywords: Non-small cell lung cancer, Elderly patients, Japan, Afatinib, EGFR mutation, Efficacy, Safety, Dose adjustment

Posted Date: December 16th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-38049/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on March 1st, 2021. See the published version at <https://doi.org/10.1186/s12885-021-07861-1>.

Abstract

Background: Lung cancer is most common among older individuals. However, polypharmacy and comorbidities, which are also more common in older individuals, can limit treatment options. Previous studies suggest that afatinib can be used safely and effectively in elderly patients. This study investigated the anti-tumour activity and safety profile of first-line afatinib in previously-untreated elderly Japanese patients with *EGFR* mutation-positive non-small cell lung cancer (NSCLC)

Methods: This was a single-arm, open-label, phase II study, performed in multiple centres in Japan. Previously untreated patients, aged ≥ 75 years, with *EGFR* mutation-positive (Del19 or L858R) advanced NSCLC were treated with afatinib 40 mg until disease progression or unacceptable toxicity. Adverse events (AEs) were managed with protocol-defined dose adjustments. The primary endpoint was objective response rate (ORR) by central review.

Results: In total, 38 patients received at least one dose of afatinib, and 37 were evaluable for response. Median age was 77.5 years (range 75–91), all patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, and 60.5% had Del19-positive disease. Median follow-up was 838 days. ORR was 75.7% (2 complete responses and 26 partial responses). Median progression-free survival was 14.2 months (95% confidence interval [CI], 9.5–19.0). Median overall survival (OS) was 35.2 months (95% CI, 35.2–not reached); the 2-year OS rate was 78.3%. The most common grade III/IV treatment-related AEs (TRAEs) were diarrhoea (28.9%), paronychia (23.7%), and rash/acne (15.8%). Dose reductions due to TRAEs were reported in 78.9% of patients, and 8 (21.1%) patients discontinued afatinib due to TRAEs. No treatment-related deaths were reported.

Conclusion: Although dose adjustments were relatively common in this small group of Japanese patients aged ≥ 75 years with *EGFR* mutation-positive NSCLC, discontinuation occurred much less frequently, and most patients were able to stay on treatment for well over a year. Further, afatinib was associated with high response rates and prolonged PFS and OS.

Trial Registration: The trial is registered with Japan Registry of Clinical Trials (JRCT) as trial number 031180136 (date of initial registration: 19 February 2019), and the University Hospital Network (UMIN) as trial number 000017877 (date of initial registration: 11 June 2015).

Background

Lung cancer is the leading cause of cancer-related death worldwide, and among men in Japan [1]. Lung cancer is most frequently diagnosed between the ages of 65 and 74 years [2]. With the population of older patients diagnosed with non-small cell lung cancer (NSCLC) increasing, the choice of first-line treatment for older patients is an important decision, which may be complicated by age-related factors such as comorbidities and polypharmacy [3]. In patients without a treatable oncogene driver, current Pan-Asian clinical practice guidelines recommend carboplatin-based doublet chemotherapy for eligible patients aged ≥ 70 years with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–

2 and adequate organ function, while single-agent chemotherapy remains the standard of care for patients not eligible for doublet chemotherapy [1]. In addition, the guidelines recommend considering immunotherapy for elderly patients who are not candidates for targeted therapy.

Epidermal growth factor receptor (EGFR) activation through tumour *EGFR* gene mutations drives malignancy in a proportion of patients with NSCLC. Activating *EGFR* mutations are found in up to 50% of NSCLC tumours from Asian populations, including in 30–40% of Japanese patients [4, 5]. Patients whose tumours harbour *EGFR* mutations may be sensitive to EGFR tyrosine kinase inhibitors (TKIs), which are recommended treatment options in this setting [1, 6, 7]. Asian treatment guidelines recommend EGFR TKI monotherapy as first-line treatment for the general population of patients with *EGFR* mutation-positive NSCLC [1, 8], and there is evidence that EGFR TKIs may be effective for some elderly patients with *EGFR* mutation-positive NSCLC [9].

Afatinib is a second-generation, irreversible ErbB-family blocker [10] that is approved in many countries, including Japan [11], for the first-line treatment of patients with *EGFR* mutation-positive NSCLC. The efficacy of afatinib in treating patients with *EGFR* mutation-positive NSCLC was established in the global, phase III LUX-Lung 3 study [12], the phase III LUX-Lung 6 study in Asian patients [13], and the global, phase IIb LUX-Lung 7 study [14, 15]. Afatinib was generally well tolerated in these studies; treatment-related adverse events (TRAEs) were mainly EGFR TKI class-related toxicities, and were managed with tolerability-guided dose reductions. Few treatment discontinuations were reported [12, 13]. Among Japanese patients in LUX-Lung 3, prolonged progression-free survival (PFS) and improved overall survival (OS) in patients with *EGFR* Del19-positive tumours was confirmed for afatinib versus platinum-based chemotherapy [16]. The safety profile of afatinib in Japanese patients was as to be expected from EGFR-TKI exposure, but a higher rate of afatinib dose reductions was observed compared with the overall LUX-Lung 3 population (76% vs. 52%) [12, 16]. In a subgroup analysis of the LUX-Lung 3, 6, and 7 studies, afatinib was effective and tolerable in patients with *EGFR* mutation-positive NSCLC, independent of age at diagnosis [3].

In addition to evidence from the LUX-Lung studies, a phase I trial including treatment at the approved dose of 40 mg, and a phase II trial employing afatinib at 30 mg support the feasibility of first-line afatinib as a treatment option in elderly Japanese patients with *EGFR* mutation-positive NSCLC [17, 18]. The aim of the current study was to further investigate the antitumour activity and safety profile of daily afatinib (40 mg) in previously untreated Japanese patients aged ≥ 75 years with *EGFR* mutation-positive NSCLC.

Methods

Study design

NEJ027 was a single-arm, multicentre, open-label, phase II study of first-line afatinib in patients aged ≥ 75 years, with *EGFR* mutation-positive NSCLC. The primary endpoint was objective response rate (ORR). Secondary endpoints were PFS, PFS in patients with *EGFR* Del19- versus L858R-positive disease, time to

treatment failure (TTF), OS, disease control rate (DCR), 1- and 2-year survival rates, and frequency of adverse events (AEs).

The study was approved by the Institutional Review Boards of all participating institutions and was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice, and local laws. All patients provided written informed consent.

The trial is registered with the Japan Registry of Clinical Trials (JRCT) as trial number 031180136, and the University Hospital Network (UMIN) as trial number 000017877.

Patients and treatment

Patients were aged ≥ 75 years, with histologically or cytologically confirmed stage III/IV disease (according to the General Rule for Clinical and Pathological Record of Lung Cancer, 7th edition) [19] or recurrent NSCLC, ≥ 1 measurable lesion (per Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) [20], and *EGFR* Del19- or L858R-positive disease (see Additional Methods). An ECOG PS of 0–1, and a life expectancy of >3 months were required. Previous treatment with chemotherapy or EGFR-targeting therapy was not allowed, and patients with active lung disease, symptomatic brain metastases and hypersensitivity to the study drug were excluded.

Patients received afatinib at a starting dose of 40 mg/day until disease progression or unacceptable toxicity. Continuation of afatinib treatment after disease progression was permitted. Appropriate prevention and management of designated AEs (diarrhoea and skin disorders) was provided through treatment interruptions and dose reductions. Dose adjustments were implemented for Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 AEs or prolonged selected grade 2 AEs (including diarrhoea, stomatitis, rash, nausea, vomiting) despite best supportive care. During treatment interruptions, afatinib was suspended until AE severity recovered to grade ≤ 1 or baseline severity. If recovery was achieved within 14 days, afatinib was resumed at a lower dose by 10-mg decrements to a minimum of 20 mg/day; otherwise, dosing was permanently discontinued. If 20 mg/day was intolerable, afatinib was permanently discontinued. The duration of treatment interruption could be longer than 14 days provided the patient had sufficiently recovered from the AE within 14 days.

Outcomes and assessments

Radiographic evaluation was performed every 8 weeks, and then every 12 weeks after 1 year. Response was assessed by extramural central review, including by the executive secretariat, according to RECIST version 1.1. Tumour response was defined as the proportion of patients with a complete response (CR) or partial response (PR). Tumour responses were confirmed by reassessment after 4 weeks.

PFS was defined as the time from registration until disease progression with first-line treatment, or death. OS was defined as time from registration until death. Best tumour response was defined without confirmation. Objective response was defined as CR or PR. Disease control was defined as CR, PR, or

stable disease. Time to treatment failure (TTF) was defined as the time from registration until discontinuation of afatinib treatment, regardless of reasons such as disease progression, adverse event (AE), and death.

AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) Japanese version 13.1 and graded using the CTCAE version 4.03 [21]. AEs were monitored throughout the study period, and worst grade was reported.

EGFR mutation analysis is described in the Additional Methods.

Statistical considerations

Simon's 2-stage minimax design was used to determine sample size. A minimum sample size of 35 patients was required based on the assumption that an expected ORR of >70% would be clinically acceptable efficacy, and <45% would be unacceptable (Additional Methods). These figures were determined based on studies available at the time the study was planned. Response rate in phase III trials comparing afatinib with conventional chemotherapy were 56–67% [12, 13], and 54–74% in elderly patients treated with first-generation EGFR TKIs [22–24]. Thus, the expected response rate was determined to be 70%. In studies of patients aged ≥ 70 years receiving conventional cytotoxic chemotherapy, response rate was 23–54% [25–28]. It was therefore determined that a response rate of 45% would be the lower threshold response rate.

The safety analysis set (SAS) included all enrolled patients who received at least one dose of afatinib. The full analysis set (FAS) comprised all patients in the SAS, excluding those who had not been evaluated after starting treatment, and those who did not have an adequately evaluated lesion. Tumour response was evaluated in the FAS. Time-to-event data are descriptive and were estimated using Kaplan–Meier methodology (Additional Methods). The last date of confirmation of survival was 18th October 2019.

The collection, management, and statistical analysis of patient data was outsourced to an independent organisation without involvement of the researchers or sponsor.

Role of the funding source

The study was funded by Nippon Boehringer Ingelheim Co. Ltd. The sponsor had no involvement in the study design, collection, analysis or interpretation of data, or in the decision to submit the article for publication.

Results

Patients

Between January 28, 2016, and September 14, 2017, 38 patients were enrolled and treated in the SAS. One patient was excluded with no appropriate measurable lesion; thus, the FAS comprised 37 patients (Additional Figure 1). Patient follow-up was completed on October 18, 2019.

In the SAS population, the median age was 77.5 years (range 75–91), 15 (39.5%) patients were male, and all patients had an ECOG PS of 0–1 (Table 1). Most comorbidities were mild, with the most frequent baseline comorbidities being hypertension in 19 (50%) patients and hyperlipidaemia in 15 (39%) patients. Other complications included diabetes mellitus, thyroid disease, and chronic obstructive pulmonary disease, in 2 patients each. More than one-third of patients (34.2%) had brain metastases. *EGFR* Del19 was more common than L858R mutation. There were no marked differences in baseline characteristics between the SAS and FAS populations (Table 1).

Table 1 Patient and disease characteristics at baseline in the safety analysis set and full analysis set

Characteristic	Safety analysis set	Full analysis set
	N = 38	N = 37
Sex		
Male	15 (39.5)	15 (40.5)
Female	23 (60.5)	22 (59.5)
Age, years		
Median (range)	77.5 (75-91)	77.0 (75-91)
Weight, kg		
Median (range)	50.2 (30.8-72.2)	50.5 (30.8-72.2)
BMI, kg/m ²		
Median (range)	21.0 (16.5-26.0)	21.2 (16.5-26.0)
Smoking status		
Never	26 (68.4)	25 (67.6)
Former/current	12 (31.6)	12 (32.4)
ECOG PS		
0	21 (55.3)	20 (54.1)
1	17 (44.7)	17 (45.9)
Histological classification		
Adenocarcinoma	38 (100)	37 (100)
Clinical stage at study entry		
IIIB	1 (2.6)	1 (2.7)
IV	28 (73.7)	28 (75.7)
Postoperative recurrence	9 (23.7)	8 (21.6)
Comorbidities		
Yes	32 (84.2)	31 (83.8)
No	6 (15.8)	6 (16.2)
Metastases at study entry		
No distant metastases	4 (10.5)	4 (10.8)
Lung	10 (26.3)	10 (27.0)
Bone	13 (34.2)	13 (35.1)
Post palliative RT	1 (2.6)	1 (2.7)

Brain	13 (34.2)	13 (35.1)
Post palliative SRS	3 (7.9)	3 (8.1)
Liver	4 (10.5)	4 (10.8)
Pleural	11 (28.9)	11 (29.7)
<i>EGFR</i> mutation categories		
Del19	23 (60.5)	22 (59.5)
L858R	15 (39.5)	15 (40.5)

Data are n (%) unless otherwise stated.

Abbreviations: *BMI* body mass index, *ECOG PS* Eastern Cooperative Oncology Group performance status, *EGFR* epidermal growth factor receptor, *RT* radiotherapy, *SRS* stereotactic radiosurgery.

Antitumour activity

Tumour response is summarised in Table 2 (Additional Figure 2 details individual patient responses for all patients in the FAS except one patient with progressive disease due to a new brain metastasis for whom the target lesion was not evaluated). The ORR was 75.7% (95% confidence interval [CI], 58.8–88.2) and was not markedly different in patients with *EGFR* Del19- versus L858R-positive tumours (72.7% vs. 80.0%). The DCR was also similar between these subgroups (86.4% vs. 93.3%).

Table 2 Tumour response

Parameter	Full analysis set N = 37	<i>EGFR</i> mutation	
		Del19 n = 22	L858R n = 15
Best response, n (%)			
CR	2 (5.4)	2 (9.1)	0
PR	26 (70.3)	14 (63.6)	12 (80.0)
SD	5 (13.5)	3 (13.6)	2 (13.3)
PD	2 (5.4)	1 (4.5)	1 (6.7)
NE	2 (5.4)	2 (9.1)	0
ORR, n (%)	28 (75.7)	16 (72.7)	12 (80.0)
(95% CI)	(58.8–88.2)	(49.8–89.3)	(51.9–95.7)
DCR, n (%)	33 (89.2)	19 (86.4)	14 (93.3)
(95% CI)	(74.6–97.0)	(65.1–97.1)	(68.1–99.8)

Abbreviations: *CI* confidence interval, *CR* complete response, *DCR* disease control rate, *EGFR* epidermal growth factor receptor, *NE* not evaluable, *ORR* objective response rate, *PD* progressive disease, *PR* partial response, *SD* stable disease.

The median follow-up period was 838 days (range 73–1156). Median PFS was 14.2 months (95% CI, 9.5–19.0). Median OS was 35.2 months (95% CI, 35.2–not reached), and 1- and 2-year OS rates were 83.8% and 78.3%, respectively. Median TTF was 18.7 months (95% CI, 10.6–22.5; Figure 1).

In patients with *EGFR* Del19- or L858R-positive tumours, median PFS was 18.2 months and 12.9 months, respectively (Additional Figure 3). Median OS was not reached in patients with Del19-positive tumours and was 35.2 months in those with L858R-positive disease; 2-year OS rates were 77.0% and 80.0%, respectively. The median TTF was 18.6 months in patients with Del19-positive tumours and 19.2 months in those with L858R-positive disease.

No significant differences in median PFS (21.4 vs 12.5 months; HR, 1.9; $p = 0.14$) or OS (not reached [NR] vs 34.8 months; HR, 0.9; $p = 0.9$) were observed between females ($n = 15$) versus males ($n = 22$). Similarly, median PFS (14.1 vs 11.0 months; HR, 1.3; $p = 0.6$) and OS (NR vs 34.8 months; HR, 0.9; $p = 0.9$) were also similar in non-smokers ($n = 25$) versus current/former smokers ($n = 12$) and patients with ECOG PS of 0 ($n = 20$) versus 1 ($n = 17$) (median PFS: 14.1 vs 11.0 months; HR, 1.4; $p = 0.4$; median OS: NR vs 34.8 months; HR, 2.2; $p = 0.1$). Median PFS (16.9 vs 3.5 months; HR, 0.20; $p = 0.001$) and OS (NR vs 10.3 months; HR, 0.09; $p < 0.001$) were significantly longer in patients who received a dose modification ($n = 29$) compared to those who did not ($n = 8$).

Patients with no comorbidities ($n = 6$) had numerically longer median PFS (16.9 vs 12.7 months; HR 1.8; $p = 0.3$) and OS (NR vs 34.8; HR, 1.3.; $p = 0.8$) than did those with at least one comorbidity ($n = 31$), however the difference was not statistically significant.

Treatment exposure and safety

In the SAS, median duration of treatment was 494 days (range 8–950). Thirty (78.9%) patients required at least one dose reduction of afatinib (Table 3). Treatment duration and afatinib dosage in individual patients is summarised in Figure 2. Twenty-eight patients discontinued afatinib treatment, mainly due to disease progression (15 patients). At data cut-off, 9 patients remained on treatment without disease progression, including the 1 patient excluded from the FAS, and 1 patient treated at < 20 mg (Additional Figure 1).

Table 3 Afatinib exposure and treatment adjustment due to treatment-related adverse events

Category	Safety analysis set N = 38
Afatinib exposure	
Median treatment duration ^a , days (range)	494 (8-950)
Median treatment days ^b , n (range)	492 (8-932)
Mean afatinib dose ^c , mg	29.7 (10.6-40.0)
Median relative dose intensity ^d , % (range)	74.2 (26.4-100)
Treatment adjustments, n (%)	
Initial treatment dose 40 mg	38 (100)
Dose reduction	30 (78.9)
Final treatment dose	
40 mg	8 (21.1)
30 mg	12 (31.6)
20 mg	14 (36.8)
30 mg QOD	1 (2.6)
20 mg QOD	3 (7.9)
Treatment interruption	28 (73.7)
Treatment discontinuation	8 (21.1)

Abbreviations: *QOD* every other day

Data are n (%) unless otherwise stated. In addition to afatinib exposure, data for dose reductions, treatment interruption and discontinuation due to TRAEs are shown.

^a From start of treatment to discontinuation or censoring, including days of treatment interruption.

^b Not including treatment interruption days.

^c Total afatinib dose/treatment duration.

^d (mean afatinib dose/40) x 100.

TRAEs are summarised in Table 4. Grade 3/4 TRAEs were reported in 28 (73.7%) patients; the most common were diarrhoea (11 [28.9%]), paronychia (9 [23.7%]), and rash/acne (6 [15.8%]). Thirty (78.9%) patients had TRAEs leading to afatinib dose reductions, and 28 (73.7%) had TRAEs leading to afatinib treatment interruptions; the most common reasons for dose reductions or interruptions were diarrhoea (26 events) and rash/acne (20 events; Figure 2). Eight (21.1%) patients discontinued treatment due to TRAEs; 4 had pneumonitis, 2 had paronychia, 1 had rash, and 1 had appetite loss and oedema. There

were 14 recorded deaths, none of which was treatment related. Thirteen patients died due to lung cancer progression and one from debility due to dementia progression.

Table 4 Treatment-related adverse events

Adverse event	Any grades	Grade I or II	Grade III or IV
Any	38 (100)	10 (26.3)	28 (73.7)
Diarrhoea	36 (94.7)	25 (65.8)	11 (28.9)
Rash/acne ^a	30 (78.9)	24 (63.2)	6 (15.8)
Paronychia	26 (68.4)	17 (44.7)	9 (23.7)
Stomatitis	26 (68.4)	21 (55.3)	5 (13.2)
Appetite loss	13 (34.2)	8 (21.1)	5 (13.2)
Vomiting	6 (15.8)	5 (13.2)	1 (2.6)
Pneumonitis	5 (13.2)	3 (7.9)	2 (5.3) ^b
Fatigue	5 (13.2)	5 (13.2)	0
Nausea	4 (10.5)	4 (10.5)	0
Oedema	4 (10.5)	4 (10.5)	0
Infection	4 (10.5)	3 (7.9)	1 (2.6)
ALT/AST increased	9 (23.7)	8 (21.1)	1 (2.6)
Creatinine increased	8 (21.1)	8 (21.1)	0
Anaemia	8 (21.1)	7 (18.4)	1 (2.6)
Hypoalbuminemia	8 (21.1)	8 (21.1)	0
Thrombocytopenia	6 (15.8)	6 (15.8)	0
Hypokalaemia	6 (15.8)	5 (13.2)	1 (2.6)
Leukocytopenia	4 (10.5)	4 (10.5)	0

Abbreviations: *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *TRAE* treatment-related adverse event.

Data are n (%) TRAEs in > 10% of patients in the safety analysis set (n = 38) listed by Medical Dictionary for Regulatory Activities (MedDRA) preferred terms and grade by Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

^a Includes papulopustular rash, rash pustular, and rash acneiform.

^b Includes one patient with grade IV pneumonitis.

Treatment after disease progression

Twelve patients with disease progression continued afatinib beyond progression for >30 days, and 1 was still receiving afatinib at data cut-off. Of the 28 patients who discontinued afatinib, 8 did not receive any further treatment, while 20 received second-line treatments (osimertinib n = 5, other EGFR-TKIs n = 7, cytotoxic agents alone n = 5, platinum-doublet chemotherapy n = 2, pembrolizumab n = 1). In total, 8 patients received osimertinib during the observation period (3 in third or later lines).

Discussion

In this study, we examined elderly patients aged ≥ 75 years (median [range] 77.5 [75–91] years); this has been identified previously as a relevant cut-off when considering the age at which more effective and tolerable therapies compared with chemotherapy are needed [3, 29]. Baseline patient and disease characteristics were largely similar to those reported in two previous investigations of afatinib in Japanese patients aged ≥ 75 years (median [range] 79 [75–87] years) [17] and >70 years (median [range] 77 [70–85] years) [18], and in a subgroup analysis of older patients in the LUX-Lung 7 study (median [range] 79 [75–86] years) [3]. However, the frequency of patients with Del19-positive disease (61%) was slightly higher than reported in elderly patients in the other two Japanese studies (20% to 55%) [17, 18], and in the LUX-Lung 7 subanalysis (37%) [3]. Most patients (84%) in the current study had comorbidities, the most common being hypertension, and more than one third (34%) had baseline brain metastases.

The ORR was 75.7%, and the primary endpoint of the study was met. Clinical activity of afatinib with respect to response and other efficacy outcomes (PFS and OS) was encouraging, consistent with other studies in elderly Japanese patients treated with afatinib in the same setting [17, 18]. Efficacy outcomes were also similar in patients with *EGFR* Del19- and L858R-positive tumours, as reported previously [18].

The safety profile of afatinib was as expected from EGFR TKI treatment in elderly Japanese patients [16, 18, 30], and was manageable with dose reductions. Previous data suggest that Japanese patients are more likely to develop pneumonitis than patients of other nationalities when treated with EGFR TKIs [31]. In the current study, 5 (13.2%) patients had treatment-related pneumonitis (1 grade 3 and 1 grade 4), 4 of whom discontinued treatment. Similarly, in a previous phase II study of elderly Japanese patients treated with afatinib, pneumonitis was reported in 4 (10%) patients, 1 of whom had grade 3 pneumonitis and 2 of whom died whilst on treatment, suggesting that elderly patients treated with an EGFR TKI should be monitored for pneumonitis [18].

The incidence of grade 3/4 TRAEs was 73.7%; this is considerably higher than the rate seen with afatinib in LUX-Lung 7 (31%; median age 63 years) [14], suggesting that patients of older age more often experience severe adverse events than younger patients with largely similar ECOG PS (0/1: 54/46% [this study] vs 32/68% [LUX-Lung 7]) Although grade 3/4 TRAEs occurred more frequently in this older population, response and survival outcomes were numerically better in our study than in LUX-Lung 7 (median PFS 14.2 vs 11.0 months; median OS 35.2 vs 27.9 months; ORR 75.7% vs 70%) [14, 15]. In a non-

interventional study involving more than 1600 Japanese patients (median age, 67 years; ECOG PS, 0/1 40/46%), grade 3/4 adverse drug reactions were reported in 36% of patients; however, ORR was much lower (40%; survival was not reported) [30].

The starting dose of afatinib in the current study was 40 mg; however, a previous phase II study in elderly Japanese patients reported acceptable tolerability and encouraging antitumour activity with a starting dose of 30 mg afatinib [18]. This raises discussion on whether the afatinib starting dose should be lower than 40 mg in older Japanese patients, and as low as 20 mg in some instances [18]. Our finding that patients who underwent dose reductions had longer PFS and OS than those who did not also suggests that a lower dose may be preferable. This latter finding, however, should be interpreted with caution. It is likely that survival was shorter in the higher-dose group because most of this group discontinued treatment early due to disease progression or adverse events. As a result of their shorter time on treatment, these patients were less likely to undergo a dose reduction. Given the high possibility of bias due to early discontinuation of afatinib, these data do not necessarily support the use of a reduced starting dose of afatinib.

While dose reductions due to AEs were more frequent in the current study compared with the previous phase II study (79% vs. 48%), rates of treatment discontinuation were comparable (21% vs. 20%). Post-hoc analyses of LUX-Lung 3, 6, and 7 showed that reductions from the afatinib 40 mg starting dose had no effect on therapeutic efficacy [32-34]. However, our findings of promising efficacy and manageable toxicity with afatinib 40 mg may argue against using a reduced starting dose in elderly Japanese patients with good performance status. Instead, starting at 40 mg and employing dose reductions may mitigate the effects of potential interpatient differences in drug pharmacokinetics/pharmacodynamics, while reducing the possibility of under treatment at lower afatinib doses. Further, using a standard dose of afatinib in elderly individuals with good performance status will simplify treatment planning and administration, and reduce the possibility of under-dosing. Use of the established tolerability-guided dose reduction protocol allows for rapid and flexible dose adjustments, helping patients remain on a higher dose for longer.

There is accumulating evidence that TKIs may be more effective in elderly than in younger patients with *EGFR* mutation-positive NSCLC [9, 33]. Moreover, given that kinase inhibitors usually show milder toxicity than cytotoxic chemotherapy, the current Japanese Lung Cancer Society guideline for stage IV NSCLC recommends (level 1C) the use of any EGFR TKI for the first-line treatment of elderly patients with a driver oncogene [8]. In this regard, afatinib may be a suitable choice for elderly patients with *EGFR* mutation-positive NSCLC who are receiving multiple concomitant medications, due to its reported low potential for drug–drug interactions, and low exposure to hepatic metabolism and excretion [35].

The interpretation of this analysis should be treated with caution due to inherent limitations of this type of study, including its single-arm design, which precluded randomisation, and retrospective nature, which meant that patients were not blinded to treatment. Further, only small numbers of patients were investigated overall and in each *EGFR* mutation subgroup. This is particularly true for the subgroup

analyses that investigated the impact of sex, smoking status, ECOG PS, dose modifications, and comorbidities on survival. Due to the small numbers of patients in some of these subgroups, the absolute values should be interpreted with caution. Perhaps most importantly, ECOG performance status was 0–1 in all patients, which resulted in a selection bias in favour of patients who may be likely to have a better outcome from treatment.

Conclusion

Although dose adjustments were relatively common in this small group of Japanese patients aged ≥ 75 years with *EGFR* mutation-positive NSCLC, discontinuation occurred less frequently, and most patients were able to stay on treatment for well over a year. Further, afatinib was associated with high response rates and prolonged PFS and OS. These findings support the use of first-line afatinib at a starting dose of 40 mg in elderly *EGFR* mutation-positive patients with NSCLC.

Abbreviations

EGFR epidermal growth factor receptor, *TKI* tyrosine kinase inhibitors, *NSCLC* non-small cell lung cancer, *AE* adverse event, *ORR* objective response rate, *DCR* disease control rate, *PFS* progression-free survival; *OS* overall survival; *TTF* time to treatment failure, *TRAE* treatment-related AE; *del19 EGFR* exon 19 deletions, *ECOG* Eastern Cooperative Oncology Group, *PS* performance status, *RECIST* Response Evaluation Criteria in Solid Tumours, *CTCAE* Common Terminology Criteria for Adverse Events, *CR* complete response, *PR* partial response, *CR* complete response, *DCR* disease control rate, *NE* not evaluable, *PD* progressive disease, *PR* partial response, *SD* stable disease, *CI* confidence interval; *MedDRA* Medical Dictionary for Regulatory Activities; *SAS* safety analysis set, *FAS* full analysis set, *BMI* body mass index, *RT* radiotherapy, *SRS* stereotactic radiosurgery, *QOD* every other day, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *NR* not reached.

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Boards of all participating institutions and was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice, and local laws. All patients provided written informed consent. The trial is registered with the Japan Registry of Clinical Trials (JRCT) as trial number 031180136, and the University Hospital Network (UMIN) as trial number 000017877.

Consent to publish

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available on reasonable request from the corresponding author.

Competing interests

O.Y. reports honoraria from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Taiho Pharmaceutical Co., Ltd., MSD, Chugai Pharmaceutical Co., Ltd., and AstraZeneca. S.S. reports honoraria from Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca, Chugai Pharmaceutical Co., Ltd., MSD, Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer, Novartis, Taiho Pharmaceutical Co., Ltd., and Kyowa Hakko Kirin Co., Ltd. S.W. reports honoraria from Eli Lilly and Company, Pfizer, Novartis, AstraZeneca, Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Boehringer Ingelheim, MSD, Ono Pharmaceutical Co., Ltd., Daiichi Sankyo and Taiho Pharmaceutical Co., Ltd. M.M. reports honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, MSD, Novartis Pharma, Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. O.H. reports honoraria from AstraZeneca, Boehringer Ingelheim and Novartis, and grants or funds from GlaxoSmithKline, AstraZeneca, Novartis, Bayer Health Care, Boehringer Ingelheim and Daiichi Sankyo. S.M. reports honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co., Ltd., Eli Lilly Japan, MSD, Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Taiho Pharmaceutical Co. Ltd., and research funding to their institution from Nippon Boehringer Ingelheim Co., Ltd. K.K. reports honoraria (speech fees) from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co. and Ono Pharmaceutical Co., Ltd. A.G. reports honoraria from Boehringer Ingelheim. Y.M., S.K. K.U. and T.N. declare no conflict of interest.

Funding

Nippon Boehringer Ingelheim Co. Ltd funded the study but were not involved in the development of the manuscript.

Authors' contributions

Y.M. contributed to study design, data acquisition, data analysis and interpretation, and manuscript preparation and review. O.Y., S.S., S.K., S.W., K.U., M.M. and O.H. contributed to data acquisition and manuscript review. T.N. contributed to study design and manuscript review. S.M. contributed to study design, statistical analysis and manuscript review. K.K. contributed to data acquisition, quality control of data and algorithms, and manuscript review. A.G. contributed to study concept and design, and manuscript editing and review. All authors approved the final version of the manuscript, and agree to be accountable for all aspects of the work.

Acknowledgements

The authors would like to thank all patients, their families, coordinators and investigators involved in this study. We also thank Hiromi Odagiri and Yukio Kakehashi (North-East Japan Study Group, Saitama, Japan) for their technical support. Independent data management and statistical analysis was entrusted to AC Medical INC. Tokyo, Japan (coordinated by Eisei Oda). Medical writing assistance funded by Boehringer Ingelheim was provided by Fiona Scott, contracted by GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this article.

Author details

¹Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 113-8603 1-1-5 Sendagi Bunkyo-Ku, Tokyo, Japan

²Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 Yamane, Hidaka City, Saitama, 350-1298 Japan

³Department of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirose-machi, Aoba-ku, Sendai, 980-0873, Japan

⁴Department of Respiratory Medicine, National Hospital Organization, Iwakuni Clinical Center, 1-1-1 Atago Cyo Iwakuni City, Yamaguchi Prefecture 740-8510, Japan

⁵Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachidori, Chuouku, Niigata, 951-8510, Japan

⁶Division of Respiriology, NTT Medical Center Tokyo, 5-9-22 Higashigotanda Shinagawa Tokyo, Japan

⁷Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka City, Osaka, 560-8552 Japan

⁸Respiratory Center, Matsusaka Municipal Hospital, 1550 Tonomachi Matsusaka City, Mie, 515-8544 Japan

⁹Tohoku University, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi, 980-8575 Japan

¹⁰Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

References

1. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. *Ann Oncol.* 2019;30(2):171–210.

2. National Cancer Institute. Surveillance, epidemiology and end results (SEER) stat fact sheets: lung and bronchus cancer. Available at: <http://seer.cancer.gov/statfacts/html/lungb.html> (Accessed 30 October 2020).
3. Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, et al. Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials. *Clin Lung Cancer*. 2018;19(4):e465–e79.
4. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. *Oncotarget*. 2016;7(48):78985–93.
5. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res*. 2015;4(1):36–54.
6. National Comprehensive Cancer Network®. NCCN Guidelines. Non-small cell lung cancer. Version 8.2020. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.8.2020 ©National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed 30 October 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. (October 2019).
7. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl4):iv192–iv237.
8. Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. *Int J Clin Oncol*. 2019;24(7):731–70.
9. Roviello G, Zanotti L, Cappelletti MR, Gobbi A, Dester M, Paganini G, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? *Clin Exp Med*. 2018;18(1):15–20.
10. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. *J Pharmacol Exp Ther*. 2012;343(2):342–50.
11. Pharmaceuticals and Medical Devices Agency. Review report: GIOTRIF® (afatinib maleate). Available at: <http://www.pmda.go.jp/files/000210320.pdf> (Accessed 30 October 2020).
12. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31(27):3327–34.
13. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2014;15(2):213–22.

14. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol.* 2016;17(5):577–89.
15. Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol.* 2017;28(2):270–7.
16. Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, et al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. *Cancer Sci.* 2015;106(9):1202–11.
17. Tanaka H, Taima K, Tanaka Y, Itoga M, Ishioka Y, Nakagawa H, et al. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. *Med Oncol.* 2018;35(3):34.
18. Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, et al. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. *Lung Cancer.* 2018;126:41–7.
19. General rule for clinical and pathological record of lung cancer, 7th edition. Kanehara & Co, Tokyo, Japan; 2010.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228–47.
21. National Cancer Institute. Common terminology criteria for adverse events v4.03. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed 30 October 2020).
22. Inoue Y, Inui N, Asada K, Karayama M, Matsuda H, Yokomura K, et al. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. *Cancer Chemother Pharmacol.* 2015;76(1):155–61.
23. Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, et al. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. *Expert Opin Pharmacother.* 2015;16(4):465–72.
24. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *J Thorac Oncol.* 2012;7(9):1417–22.
25. Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. *J Clin Oncol.* 2015;33(6):575–81.
26. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the

- West Japan Thoracic Oncology Group Trial (WJTOG 9904). *J Clin Oncol*. 2006;24(22):3657–63.
27. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. *Lancet*. 2011;378(9796):1079–88.
 28. Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, et al. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801. *Oncologist*. 2014;19(4):352–3.
 29. Hohenforst-Schmidt W, Zarogoulidis P, Steinheimer M, Benhassen N, Tsiouda T, Baka S, et al. Tyrosine kinase inhibitors for the elderly. *J Cancer*. 2016;7(6):687–93.
 30. Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, et al. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. *Int J Clin Oncol*. 2019;24(8):917–26.
 31. Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. *Lung Cancer*. 2018;123:60–9.
 32. Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. *Ann Oncol*. 2016;27(11):2103–10.
 33. Halmos B, Tan EH, Soo RA, Cadranell J, Lee MK, Foucher P, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). *Lung Cancer*. 2019;127:103–11.
 34. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. *J Cancer Res Clin Oncol*. 2019;145(6):1569–79.
 35. Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. *Cancer Chemother Pharmacol*. 2014;74(2):267–75.

Figures




Figure 1

Kaplan–Meier Survival Analysis In The Full Analysis Set (n = 37). (A) Progression-free Survival (PFS)a. (B) Overall Survival (OS). (C) Time to Treatment Failure (TTF). Abbreviations: CI = confidence interval; NR = not reached; QOD = every other day. aPFS was Censored for 4 Patients Receiving Afatinib < 20 mg/day. These Patients Were Treated as Censored When They Fell below the 20 mg/day Minimum Dose Specified in the Protocol.




Figure 2

Treatment Duration and Afatinib Dose in the Safety Analysis Set (n = 38). Abbreviations: AE = adverse event; CR = complete response; NE = not evaluable; OT = other; PD = progressive disease; PR = partial response; QOD = every other day; SD = stable disease. ^aFor Patient 21, Protocol Treatment was Discontinued Due to Disease Progression; Thereafter, Afatinib Treatment Beyond PD was Discontinued Due to Skin Disorders. ^bOne Patient Had No Appropriate Measurable Lesion and was not Included in the Full Analysis Set.